Fat Loss & Weight Management

Where to Buy Retatrutide: Price & Vendor Guide

One vendor sells 60mg vials at half the per-mg cost of 12mg — but COA matters more than price. Vial sizes, cost per week, and vendor scores.

Retatrutide Cycle Protocol: Length, Taper, Off-Cycle

Community sources cluster around 8-on / 8-off. Covers cycle length, week-by-week titration, tapering, off-cycle reports, and restart protocols.

SLU-PP-332 Reconstitution: Vial Mixing & Oral Cap Notes

Ion's 30 mg vial is the only injectable path. Oral caps need no mixing — but the published bioavailability question changes the math entirely.

SLU-PP-332 Dosage Chart: 500 mcg–1.5 mg Daily SC

Community SubQ protocols run 500–1,500 mcg/day, derived from mouse-to-human dose scaling. Why oral capsules likely fail and how the math gets there.

Compounded GLP-1s: FDA Docket Closed, 3,901 Comments

The FDA's plan to bar 503B bulk compounding of semaglutide, tirzepatide and liraglutide drew 3,901 comments before the July 30 cutoff. What survives.

FDA Maps Generic Path for Semaglutide, Tirzepatide

The FDA published 17 revised generic-peptide guidances and pulled its 2021 synthetic-peptide rule. What it changes for GLP-1 pricing and access.

Novo Sues Lilly Over GLP-1 Ads: The Dose Mismatch

Novo asked a court to halt Lilly's GLP-1 ads for pitting max-dose tirzepatide against outdated semaglutide doses. What the trial data actually shows.

Retatrutide TRIUMPH-2/3: 22.6% Loss in Diabetes & CVD

Lilly's retatrutide met endpoints in two new Phase 3 trials — up to 22.6% weight loss in obesity with diabetes and heart disease. What buyers should know.

Where to Buy Bioglutide (NA-931): 2026 Status

Bioglutide (NA-931) isn't for sale yet — it's still in trials. See the real 2026 availability, why current listings aren't legit, and get launch alerts.

Where to Buy Survodutide: Price & Vendor Guide

BI 456906 dual agonist pricing, why 10mg vials are the norm, and what a real 4,610 Da COA proves. Vendor picks and $/mg benchmarks inside.

Where to Buy Cagrilintide: Price & Vendor Guide

Why 5mg vials suit weekly dosing, what a 3,749 Da COA must show, and per-mg pricing for the amylin analog behind CagriSema. Vendor picks inside.

Peptide Stacks Under $200/Month

4 complete peptide protocols under $200/month — fat loss, healing, anti-aging, sleep. Per-peptide cost math, vendor picks, and which vial to buy.

What Is Bioglutide (NA-931)? Oral GLP-4 Agonist

Bioglutide (NA-931): the oral quadruple agonist adding IGF-1 to retatrutide's targets. What the ADA 2025 trial data reported, and the accessible analog.

Bioglutide (NA-931) Phase 2: 13.8% Oral Weight Loss

The Phase 2 trial reported oral quadruple agonist NA-931 hit 13.8% weight loss with no muscle loss. How it stacks up to retatrutide.

Quintuple Agonist Beats Retatrutide in Rats: VRX-0075

A 5-receptor obesity peptide, VRX-0075, beat retatrutide for weight loss in obese rats at ADA 2026. What the data means and what you can buy now.

Enicepatide: Roche's CT-388 Hits 22.5% at ADA 2026

Roche's enicepatide (CT-388) hit 22.5% placebo-adjusted weight loss at ADA 2026. What the dual GLP-1/GIP data means for buyers right now.

GLP-4 vs GLP-5: Bioglutide vs VRX-0075

Bioglutide (GLP-4) adds muscle-sparing IGF-1 and has oral human data; VRX-0075 (GLP-5) adds amylin for deeper loss but is rat-only. Full comparison.

Bioglutide vs Retatrutide: Oral Quad vs Injectable

Bioglutide (NA-931) is an oral quadruple agonist; retatrutide an injectable triple. How the two obesity compounds actually compare in 2026.

SLU-PP-332 vs MOTS-c: Two Exercise Mimetics

Synthetic ERR pan-agonist vs mitochondria-encoded AMPK activator. Same goal, opposite philosophies, and the stack rationale that ties them.

Cagri+Tirz vs Cagri+Sema: Amylin Pairing Choice

REDEFINE 1 hit 22.7% with cagrilintide + semaglutide. Cagrilintide + tirzepatide has stronger GIP. Mechanistic case, trial data, and the open question.

Bioglutide (NA-931) Trial Results Timeline

Bioglutide (NA-931) trials reported up to 13.8% weight loss by week 13. How the oral quadruple agonist's results built across Phase 1 and Phase 2.

Tesofensine Results: Week-by-Week Timeline

Appetite suppression in days, weight loss over months. What the Phase 2 trial documented week 1 through month 6 at 0.5mg/day oral.

Survodutide Results: Week-by-Week Timeline

Appetite drops in week 1, but the 18.7% weight-loss figure took 46 weeks of titration. Full trial-reported timeline by phase and use case.

Liraglutide Results: Week-by-Week Timeline

Appetite shifts in week 1, but trial weight loss took 56 weeks. The full daily-injection timeline by phase, grounded in the SCALE trial data.

Bioglutide (NA-931) Dosage: What Trials Used

Bioglutide (NA-931) is oral, not injected. See the exact dose the Phase 2 trial used for 13.8% weight loss — and why no research-use protocol exists yet.

Bioglutide (NA-931) Benefits: Oral, No Muscle Loss

Bioglutide (NA-931) is oral, once-daily. Phase 2 subjects on 150mg/day averaged 13.8% weight loss with no muscle loss reported. What the trial data shows.

SLU-PP-332: Mice Lost 12% Body Weight in 30 Days

DIO mice on SLU-PP-332 ran 70% longer and gained 10x less fat than controls. What ERR pan-agonism does, plus the asterisks behind the data.

Retatrutide + Cagrilintide Benefits: 4 Pathways

GLP-1, GIP, glucagon, plus amylin — four metabolic axes in one stack. What the per-component trial data implies about combined effect.

Tirzepatide: 22.5% Weight Loss + Liver Fat

Weight loss gets the headlines, but tirzepatide's liver fat data may matter more. 8 research-backed effects with cited studies.

Tesamorelin Side Effects: HIV Trial Data Breakdown

Injection-site reactions hit 25% in Phase 3. Joint pain and elevated IGF-1 follow. Full FDA-label safety breakdown.

5-Amino-1MQ Side Effects: What Research Shows

Animal models report clean safety. Community data adds mild GI and transient fatigue. Full breakdown of investigational dataset.

SLU-PP-332 Side Effects: Zero Human Data, Mouse Signals

No human Phase 1, no incidence rates. What the mouse studies and ERR receptor expression actually predict — cardiac, hepatic, and the unknown long tail.

RetaCagri Side Effects: Combined GI Burden + Dysesthesia

Both compounds slow gastric emptying via different pathways — combined nausea is the rate-limiter. Plus retatrutide's dysesthesia signal ≥9mg.

Retatrutide vs Semaglutide: Triple vs Single Agonist

Phase 2 trials reported 24.2% weight loss for retatrutide vs 14.9% for semaglutide in STEP 1 — but only one is FDA-approved. Full side-by-side.

Liraglutide vs Semaglutide: 2.5x Weight Loss Gap

STEP 8 head-to-head: 15.8% vs 6.4% weight loss. Side-by-side dosing, side effects, and cost — and which one to actually pick.

Cagrilintide vs Semaglutide: Different Paths

They target different receptors entirely — and combining them produces 22.7% weight loss. Mechanism, efficacy, and when to use each.

SLU-PP-332 + Retatrutide Stack: Eat Less, Burn More

Triple-agonist appetite suppression + ERR pan-agonist mitochondrial output. Why community references frame it as the cleanest mechanistic pair.

SLU-PP-332 Bloodwork: 7 Labs Researchers Track

Lactate may be the marker that tells you if ERR pan-agonism is doing anything. Cardiac, metabolic, and liver labs published preclinical work tracked.

Tirzepatide Bloodwork: 7 Labs to Track

Most skip calcitonin — the one marker that catches the rarest but most serious risk. 7 essential labs with optimal ranges and testing schedule.

Tesamorelin Bloodwork: 7 Labs to Track

Most skip IGF-1 — the one marker that tells you if tesamorelin is actually working. 7 essential labs with optimal ranges and testing cadence.

Survodutide Bloodwork: 8 Labs to Track

Liver enzymes are the one most skip — and shouldn't with a glucagon agonist. 8 essential labs with optimal ranges and testing schedule.

$30 vs $300 Semaglutide: Where the Money Goes

Same Chinese factories, 10x price gap. We break down every dollar of compounded GLP-1 markup — what's real safety value vs telehealth marketing.

Tesamorelin Reconstitution: 2mg + 2mL Chart

Full vial = one dose at standard concentration. Step-by-step tesamorelin mixing with dilution chart, syringe math, and storage.

Retatrutide vs Tirzepatide: One Clear Winner

Triple vs dual receptor agonist showdown. Retatrutide hit 24% weight loss vs tirzepatide's 22.5% — but that's not the whole story.